Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px

Person › Details

John Dawson (Oxford Biomedica plc (LSE: OXB))

Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)

	Organisation	Oxford Biomedica plc (LSE: OXB)
	Group	Oxford Biomedica (Group)
	Former/major organisation	Cephalon Europe
	Today	Teva (Group)
	Group	Teva (Group)
	Product	TroVax®
	Product 2	ProSavin®

Record changed: 2020-06-08

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for John Dawson

[1] Oxford Biomedica plc. (6/8/20). "Press Release: Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre". Oxford....
[2] Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford....
[3] Oxford Biomedica plc. (3/18/20). "Press Release: Oxford BioMedica Signs License & Clinical Supply Agreement with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for LentiVector Platform for CAR-T and TCR-T Therapeutics". Oxford....
[4] Oxford Biomedica plc. (5/28/19). "Press Release: Oxford BioMedica Announces Strategic Investment by Novo Holdings A/S". Oxford....
[5] Oxford Biomedica plc. (3/14/19). "Press Release: Oxford Biomedica plc Preliminary Results for the Year Ended 31 December 2018". Oxford....
[6] Oxford Biomedica plc. (2/7/19). "Press Release: Oxford Biomedica Provides Update on Programmes Outlicensed to Sanofi". Oxford....
[7] Oxford Biomedica plc. (11/23/18). "Press Release: Oxford BioMedica Announces New Digital Framework Initiative to Streamline the Production of Next-generation Medicines with Cash Injection from Innovate UK". Oxford....
[8] Boehringer Ingelheim. (8/6/18). "Press Release: Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis". Ingelhei...
[9] Oxford Biomedica plc. (6/6/18). "Press Release: Oxford BioMedica and Axovant Sciences Enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease". Oxford....
[10] Oxford Biomedica plc. (2/15/18). "Press Release: Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy". Oxford....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]